A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. [electronic resource]
Producer: 20140106Description: 2574-8 p. digitalISSN:- 1532-1827
- Administration, Metronomic
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzamides -- administration & dosage
- Chordoma -- drug therapy
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Feasibility Studies
- Female
- Gastrointestinal Neoplasms -- drug therapy
- Humans
- Imatinib Mesylate
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Molecular Targeted Therapy -- methods
- Neoplasms -- drug therapy
- Piperazines -- administration & dosage
- Pyrimidines -- administration & dosage
- Skin Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.